1. Liu, Qun, Liu, Heshu, Huang, Xuying, Miao, Jinwei, Liu, Jian. 2022. A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer. In Cancer gene therapy, 30, 192-208. doi:10.1038/s41417-022-00538-2. https://pubmed.ncbi.nlm.nih.gov/36151333/
2. Guruvaiah, Praveen, Chava, Suresh, Sun, Chiao-Wang, Penn, Courtney A, Gupta, Romi. 2023. ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE. In Cell death & disease, 14, 456. doi:10.1038/s41419-023-05993-9. https://pubmed.ncbi.nlm.nih.gov/37479754/
3. Wang, Tao, Perazza, Daniel, Boussouar, Fayçal, Verdel, André, Khochbin, Saadi. 2021. ATAD2 controls chromatin-bound HIRA turnover. In Life science alliance, 4, . doi:10.26508/lsa.202101151. https://pubmed.ncbi.nlm.nih.gov/34580178/
4. Liu, Qun, Liu, Heshu, Li, Lina, Wen, Tao, Liu, Jian. 2019. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation. In International journal of oncology, 56, 219-231. doi:10.3892/ijo.2019.4913. https://pubmed.ncbi.nlm.nih.gov/31746426/
5. Hao, Shengyu, Li, Fan, Jiang, Pan, Gao, Jian. 2022. Effect of chronic intermittent hypoxia-induced HIF-1α/ATAD2 expression on lung cancer stemness. In Cellular & molecular biology letters, 27, 44. doi:10.1186/s11658-022-00345-5. https://pubmed.ncbi.nlm.nih.gov/35672694/
6. Wu, Gang, Lu, Xiaojun, Wang, Yawei, Zhen, Kunming, Liu, Yongfeng. 2014. Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma. In International journal of oncology, 45, 351-61. doi:10.3892/ijo.2014.2416. https://pubmed.ncbi.nlm.nih.gov/24805933/
智鼠故事 
